The University of Hong Kong-Shenzhen Hospital is a large, comprehensive public hospital fully invested by the Shenzhen Municipal Government and introduced into the modern management model of the University of Hong Kong. The total investment of the hospital is about 4 billion yuan, covering an area of 192,000 square meters and a total building area of 367,000 square meters. The hospital now has 2000 beds, and has started the second phase of the project, which will be increased to 3000 beds in the future.
The hospital began to operate on July 1, 2012, gradually introducing international first-class advanced hospital management experience and medical technology to provide high-quality medical services to the public. Taking the opportunity of Shenzhen-Hong Kong cooperation as an opportunity, the hospital has fully introduced the superior disciplines of the University of Hong Kong with the first-class international level. At the same time, the hospital established an international medical center to provide advanced international high-end medical and health management services, and established Huawei Social Health Center to provide primary medical services to meet the multilayered, diversified and individualized medical service needs of citizens, Hong Kong cross-border personnel and foreigners.
The hospital was accredited by the Australian Council of Healthcare Standards (ACHS) in September 2015 and officially became a national tertiary A general hospital in November 2017. In June 2018, the hospital was successfully enrolled in the high-level hospital construction unit in Guangdong Province, and made every effort to create four internationalization centers in the Great Bay Area of Guangdong, Hong Kong and Macao, which integrates "medical, teaching, research and management", including a medical center, a medical personnel training center, a medical science and technology innovation centers and a hospital management innovation center.
In order to meet the needs of citizens and foreigners for diversified medical services, the University of Hong Kong-Shenzhen Hospital established an "international medical center" to provide advanced international level and high-end medical services focusing on humanistic care. The international medical center was established in 2013. The construction area of the international medical center was about 35,000 square meters. The first floor was an outpatient department, the second to the fifth floor was the inpatient department and the high-end physical examination department, providing comprehensive high-end medical services. With the purpose of patient's needs, the international medical center focuses on developing diversified and individualized star-rated medical services and strives to become the industry benchmark of high-end medical services.
The Department of Hematology, the University of Hong Kong-Shenzhen Hospital, was founded in March 2013 by Professor Zhimei Zhu, who returned from the Department of Hematology, Royal Liverpool University, United Kingdom. Under the leadership of Professor Zhimei Zhu, the Department of Hematology is composed of 12 specialists, 4 hematopoietic stem cell transplantation laboratory technicians and 27 nursing staff. The hematology department has a general hematology ward (43 general beds), a hematopoietic stem cell transplantation ward (9 laminar flow beds), a hematopoietic stem cell transplantation laboratory, and a blood cell isolation unit. In the physician team, there are 4 doctors with the title of associate chief physician or above, 1 postdoctor, 4 doctors with doctoral degree, 4 doctors with master‘s degree, 3 senior doctors. The doctors are very skilled. We will actively follow the development of international disciplines, follow domestic and foreign guidelines, update the concept of diagnosis and treatment, focusing on comprehensive diagnosis and treatment of hematological tumors, and intensify the individualized treatment of patients with hematological diseases such as leukemia, lymphoma, myeloma MDS, aplastic anemia, ITP, etc. The special diagnosis and treatment carried out by the hematology department include the CART program. The hematology department is also the first unit in Shenzhen to develop commercial CART for malignant lymphoma. In the “Hong Kong-Macao Drug and Device Trade”, the latest drugs and the most advanced devices in the world are introduced for clinical application. We actively develop MDT discussion systems for difficult and rare diseases. Clinical studies of autologous transplantation for the treatment of autoimmune diseases were conducted in collaboration with Kinghorn Cancer Centre, Australia. The department cooperated with Hong Kong Mary Hospital to conduct clinical studies of new drugs for leukemia. The department focuses on the development of hematopoietic stem cell transplantation for the treatment of hematologic malignancies. At present, the department can carry out various types of transplantation (autologous transplantation, allogeneic transplantation, sibling identical and HLA-mismatched, haploid, unrelated donor transplantation, peripheral blood hematopoietic stem cell, bone marrow and cord blood transplantation, etc.), and the level of transplantation has reached the leading level in China.
- Deputy Director of Lymphoma Committee of Shenzhen Anticancer Society (2017-present)
- Medical Director and Consultant hematologist, Royal Liverpool Hospital, United Kingdom (1990-2012)
- Vice Chairman, Professional Committee of Biotherapeutics in China Research Hospitals
- Fellow, Royal College of Pathology, FRCPath
- Fellow, College of Internal Medicine, London, UK, FRCP (London)
- Fellow, School of Internal Medicine, Edinburgh, UK, FRCP (Edin)
- Bachelor of Medicine, University of Hong Kong, MB BS (Hong Kong)
